3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
53
Ovarian Neoplasms
4
Prostatic Neoplasms
3
Neoplasms
3
Inflammatory Breast Neoplasms
3
HER2-positive Breast Cancer
3
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Solid Tumor
2
Rectal Neoplasms
2
Neoplasm Metastasis
2
Colonic Neoplasms
2
Urinary Bladder Neoplasms
1
Solid Cancers
1
Patient Preference
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms, Unknown Primary
1
Multiple Endocrine Neoplasia
1
Malignant Solid Neoplasm
1
Lung Neoplasms
1
Locally Advanced Breast Cancer
1
Her2-Positive Breast Cancer
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Early Breast Cancer
1
HER2-Positive Early Breast Cancer
1
HER2 Positive Breast Cancer
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
37
Paclitaxel
36
Carboplatin
31
Cyclophosphamide
22
Albumin-Bound Paclitaxel
20
atezolizumab
16
130-nm albumin-bound paclitaxel
16
Taxes
15
Doxorubicin
15
Cisplatin
13
Capecitabine
13
Nivolumab
10
Docetaxel
8
olaparib
7
Gemcitabine
6
Everolimus
6
talazoparib
5
durvalumab
5
Magnetic Resonance Spectroscopy
5
Biopsy
5
Bevacizumab
5
veliparib
4
spartalizumab
4
sacituzumab govitecan
4
pegfilgrastim
4
liposomal doxorubicin
4
eribulin
4
Specimen Handling
4
Immunoglobulin G
4
trilaciclib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Triple Negative Breast Neoplasms
×
pertuzumab
×
Clear all
No trials found.